STOCK TITAN

Lineage Cell Therapeutics Inc - LCTX STOCK NEWS

Welcome to our dedicated news page for Lineage Cell Therapeutics (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lineage Cell Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lineage Cell Therapeutics's position in the market.

Rhea-AI Summary
Lineage Cell Therapeutics, Inc. receives FDA clearance for Investigational New Drug amendment for OPC1, an investigational allogeneic oligodendrocyte progenitor cell transplant for spinal cord injury. The company plans to conduct the DOSED clinical study to evaluate a novel delivery device in subacute and chronic SCI patients, with the first clinical site expected to open in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
clinical trial
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) closes a registered direct offering, selling 13,461,540 common shares at $1.04 per share, raising $14.0 million. Broadwood Partners and Don M. Bailey, board members, participated. The offering aims to bolster the balance sheet for upcoming milestones without dilutive elements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) has announced a registered direct offering of 13,461,540 common shares at an offering price of $1.04 per share. The agreement with investors was entered into before the markets opened on February 6, 2024. The closing of the offering is expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.73%
Tags
offering
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) announced positive results from a Phase 1/2a clinical study for OpRegen in treating geographic atrophy (GA) secondary to advanced age-related macular degeneration (AMD). The study showed retinal structure improvements, with the data set to be presented at the 2024 Angiogenesis, Exudation, and Degeneration Meeting. The virtual meeting, sponsored by the University of Miami Health System Bascom Palmer Eye Institute, will feature the presentation by Allen Ho, MD, FACS, FASRS, on behalf of Roche and Genentech.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
clinical trial
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) submits an Investigational New Drug amendment (INDa) to the U.S. FDA for OPC1, its allogeneic oligodendrocyte progenitor cell transplant, for spinal cord injury treatment. The company plans to initiate the DOSED clinical study to evaluate the safety and utility of a novel spinal cord delivery device. OPC1 aims to improve the quality of life and restore functional activity in traumatic cervical or thoracic SCI patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.48%
Tags
none
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) reported financial and operating results, including updates on the Phase 2a clinical study of RG6501 (OpRegen®) in patients with Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) under management of Genentech, a Member of the Roche Group. The company also presented additional OpRegen data at the 23rd Annual EURETINA Congress and 2023 Eyecelerator Meetings. Key highlights include rapid improvement in outer retinal structure in patients, U.S. Patent issuance for manufacturing and differentiation process for retinal pigment epithelial (RPE) cells, and ongoing development activities for OPC1 and a hypoimmune pluripotent cell line for neurology indications in partnership with Eterna Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
earnings
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. will report its third quarter 2023 financial and operating results on November 9, 2023. A conference call and webcast will be held to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences earnings
-
Rhea-AI Summary
Lineage Cell Therapeutics to present at Eyecelerator 2023 and announces positive results from clinical study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
clinical trial
-
Rhea-AI Summary
Lineage Cell Therapeutics announces issuance of U.S. Patent for Large Scale Production of Retinal Pigment Epithelial Cells
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Lineage Cell Therapeutics announces issuance of U.S. Patent for Large Scale Production of Retinal Pigment Epithelial Cells
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
Lineage Cell Therapeutics Inc

NYSE:LCTX

LCTX Rankings

LCTX Stock Data

205.44M
129.53M
4.13%
43.98%
4.83%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Carlsbad

About LCTX

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.